Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
Monte Rosa Therapeutics presented new preclinical data regarding its MRT-8102 program at the ACR Convergence 2026 conference.
Stocks · News reference
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics reported its third-quarter 2026 financial results, highlighting clinical progress for its molecular glue degrader pipeline and a strong cash position.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026
Wells Fargo Maintains Buy Rating on Monte Rosa Therapeutics, Lowers Price Target
Wells Fargo analyst Derek Archila has maintained a 'Buy' rating on Monte Rosa Therapeutics while adjusting the price target from $29 to $25.
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25
Monte Rosa Therapeutics Grants Inducement Equity Awards to New Employees
Monte Rosa Therapeutics announced the grant of inducement equity awards to four newly hired non-executive employees.
Monte Rosa Therapeutics Reports Inducement Grants
Monte Rosa Therapeutics announced the issuance of equity-based inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4).